title: The in-vivo activity of co-amoxiclav with netilmicin against experimental methicillin and gentamicin resistant Staphylococcus epidermidis infection in rabbits.
abstract: This study compared co-amoxiclav, vancomycin and teicoplanin with and without netilmicin or amikacin for treating experimental subcutaneous fibrin-clot infection in rabbits due to a clinical beta-lactamase-positive methicillin- and gentamicin-resistant Staphylococcus epidermidis strain (MGRSE). MICs (mg/L) for this strain were: oxacillin 125, gentamicin 32, vancomycin 4, teicoplanin 8, netilmicin 1, amikacin 4, amoxycillin 64 with clavulanate at 2 mg/L. In rabbits treated with a single-dose i.v. regimen (netilmicin 8 mg/kg, amikacin 20 mg/kg, vancomycin 30 mg/kg, teicoplanin 15 mg/kg, co-amoxiclav 150-30 mg/kg), the bacterial count 24 h post-dose was reduced whatever the combination used (ANOVA, P < or = 0.001). Regimens were statistically classified in decreasing order of efficacy as follows: co-amoxiclav combined with netilmicin > vancomycin either alone or combined with either netilmicin or amikacin, teicoplanin with netilmicin > netilmicin and co-amoxiclav alone > teicoplanin or co-amoxiclav combined with amikacin, and teicoplanin alone > amikacin > no drug. From these findings, it is concluded that: co-amoxiclav could be useful for the treatment of beta-lactamase-positive and methicillin-resistant S. epidermidis infection; some enzyme-resistant aminoglycoside could be considered for treating gentamicin-resistant but netilmicin/amikacin-sensitive S. epidermidis infection; the combination of co-amoxiclav with netilmicin was synergistic and more rapidly bactericidal than vancomycin in this animal model.
authors.affiliation: Department of Infectious Diseases, CHRU Hopital du Bocage, Dijon, France.
authors.forename: P
authors.initials: P
authors.lastname: Chavanet
authors.forename: F
authors.initials: F
authors.lastname: Collin
authors.forename: E
authors.initials: E
authors.lastname: Muggeo
authors.forename: B
authors.initials: B
authors.lastname: Gagelin
authors.forename: P
authors.initials: P
authors.lastname: Chassin
authors.forename: V
authors.initials: V
authors.lastname: Kosmidis
authors.forename: A
authors.initials: A
authors.lastname: Bernard
authors.forename: J P
authors.initials: JP
authors.lastname: Kistermann
authors.forename: H
authors.initials: H
authors.lastname: Portier
mesh_terms: D000658:Amoxicillin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D019980:Amoxicillin-Potassium Clavulanate Combination; D000818:Animals; D002969:Clavulanic Acids / Q000493:pharmacokinetics / Q000627:therapeutic use*; D004338:Drug Combinations; D004352:Drug Resistance, Microbial; D005839:Gentamicins / Q000494:pharmacology*; D016106:Methicillin Resistance; D008954:Models, Biological; D009428:Netilmicin / Q000493:pharmacokinetics / Q000627:therapeutic use*; D011817:Rabbits; D013203:Staphylococcal Infections / Q000188:drug therapy*; D013212:Staphylococcus epidermidis / Q000187:drug effects*
chemical_list: D002969:Clavulanic Acids; D004338:Drug Combinations; D005839:Gentamicins; D009428:Netilmicin; D019980:Amoxicillin-Potassium Clavulanate Combination; D000658:Amoxicillin